Model N Introduces New Rebate Enhancement, as Pharma Companies Prepare for Impact From the Inflation Reduction Act
Model N Introduces New Rebate Enhancement, as Pharma Companies Prepare for Impact From the Inflation Reduction Act
New Medicare Part D inflation rebate enhancement helps pharma manufacturers manage pricing reforms
新的Medicare D部分通脹回扣增強措施可幫助製藥製造商管理定價改革
SAN MATEO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Model N (NYSE: MODN), the leader in revenue optimization and compliance has introduced a critical product enhancement that supports evolving compliance needs around the Inflation Reduction Act (IRA). The company has introduced a new Medicare Part D inflation rebate-per-unit, ensuring pharma manufacturers remain compliant with impending IRA regulation and avoid significant revenue loss.
加利福尼亞州聖馬特奧，2024年5月7日（GLOBE NEWSWIRE）——收入優化與合規領域的領導者Model N（紐約證券交易所代碼：MODN）推出了一項關鍵產品增強措施，以支持圍繞《通貨膨脹降低法》（IRA）不斷變化的合規需求。該公司推出了新的每單位Medicare D部分通貨膨脹回扣，確保製藥製造商遵守即將出臺的IRA法規，避免重大收入損失。
"The Inflation Reduction Act introduces sweeping changes for drug pricing and Medicare programs, and our goal is to empower customers to stay ahead of these shifts," said Suresh Kannan, Chief Product Officer at Model N. "As our life sciences customers prepare for new reforms and regulatory changes, Model N's latest product innovations address a critical market need by providing the capabilities necessary to calculate and process complex Medicare Part D inflation rebates."
Model N首席產品官蘇雷什·坎南說：“《通貨膨脹降低法》對藥品定價和醫療保險計劃進行了全面的變革，我們的目標是使客戶能夠在這些變化中保持領先地位，在我們的生命科學客戶爲新的改革和監管變化做準備之際，Model N的最新產品創新通過提供計算和處理複雜的Medicare D部分通脹回扣所需的能力來滿足關鍵的市場需求。”
According to Model N's 2024 State of Revenue Report, pharmaceutical executives are preparing for a significant revenue impact from the IRA. The law aims to lower prescription drug costs for Medicare beneficiaries through provisions allowing the program to negotiate prices for certain high-cost drugs and requiring manufacturers to pay rebates for any price changes higher than the inflation rate. Effective for Medicare Part B and D drugs, manufacturers must calculate inflation penalties based on pricing increases over the designated benchmark periods.
根據Model N的2024年收入狀況報告，製藥業高管正在爲IRA的重大收入影響做準備。該法律旨在通過允許該計劃談判某些高成本藥物的價格並要求製造商爲任何高於通貨膨脹率的價格變動支付回扣的條款，降低醫療保險受益人的處方藥成本。對Medicare B部分和D部分藥物有效，製造商必須根據指定基準期內的價格上漲來計算通貨膨脹罰款。
Model N's new inflation rebate feature empowers customers to calculate Medicare Part D inflation rebate-per-unit, ensuring compliance with the upcoming IRA regulation set to take effect in 2025. Coupled with Model N's Government Pricing, Payer Management, Provider Management, and Validata solutions, customers gain a unified, end-to-end process to manage pricing strategy, calculate fees, and issue rebate payments in compliance with IRA guidance.
Model N的新通脹回扣功能使客戶能夠計算每單位的Medicare D部分通貨膨脹回扣，從而確保遵守即將於2025年生效的IRA法規。再加上Model N的政府定價、付款人管理、提供商管理和Validata解決方案，客戶將獲得統一的端到端流程，按照IRA指南管理定價策略、計算費用和發放返利。
The company is committed to ensuring that pharma customers are equipped with the most up-to-date technology to comply with IRA guidance, which will continue to evolve into 2026. With continual enhancements to its suite of life sciences cloud solutions, Model N ensures pharma customers can nimbly adapt to evolving regulations while optimizing revenue.
該公司致力於確保製藥客戶配備最新的技術，以遵守IRA指導方針，該指導方針將持續發展到2026年。通過不斷增強其生命科學雲解決方案套件，Model N確保製藥客戶能夠靈活地適應不斷變化的法規，同時優化收入。
For more information on Model N's latest product innovations, visit
有關 Model N 最新產品創新的更多信息，請訪問
###
###
About Model N
Model N is the leader in revenue optimization and compliance for pharmaceutical, medtech and high-tech innovators. Our intelligent platform powers your digital transformation with integrated technology, data, analytics, and expert services that deliver deep insight and control.
關於 Model N
Model N是製藥、醫療技術和高科技創新者收入優化和合規方面的領導者。我們的智能平台利用集成的技術、數據、分析和專家服務，爲您的數字化轉型提供深刻的見解和控制。
Our integrated cloud solution is proven to automate pricing, incentive and contract decisions to scale business profitably and grow revenue. Model N is trusted across more than 120 countries by the world's leading pharmaceutical, medical technology, semiconductor, and high-tech companies, including Johnson & Johnson, AstraZeneca, Stryker, Seagate Technology, Broadcom, and Microchip Technology. For more information, visit .
事實證明，我們的集成雲解決方案可以自動進行定價、激勵和合同決策，從而實現業務盈利並增加收入。Model N在120多個國家受到世界領先的製藥、醫療技術、半導體和高科技公司的信任，包括強生、阿斯利康、史賽克、希捷科技、博通和微芯科技。欲了解更多信息，請訪問。
CONTACT: Public Relations BLASTmedia modeln@blastmedia.com Investor Relations Carolyn Bass investorrelations@modeln.com
聯繫人：公共關係 BlastMedia modeln@blastmedia.com 投資者關係 Carolyn Bass investorrelations@modeln.com
譯文內容由第三人軟體翻譯。